March 31, 2016—Twelve Members of Congress are urging the National Institutes of Health to respond favorably to a petition to use its statutory authority to lower the price of an expensive prostate cancer drug developed with taxpayer support.
You must be registered to read complete articles (it's quick, easy, and 100% free). Click here to register. Already registered? Click here to login. (340B Health members, Drug Discount Monitor subscribers, and 340B Coalition conference attendees: Use your existing username and password.)